Abiopharma

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Entrada Therapeutics to Present at Upcoming Investor Conferences

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Regeneron Reports Third Quarter 2025 Financial and Operating Results

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025